Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic progenitor cells
- Development stage
- Phase 1
- Lead developer
- Mounzer Agha
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous hematopoietic progenitor cells (HPCs) are utilized as a cellular therapy in a specialized treatment protocol for refractory Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis). Developed by Mounzer Agha, the approach involves harvesting the patient's own CD34+ stem cells, followed by an intensive immuno-ablative conditioning regimen consisting of high-dose cyclophosphamide, antithymocyte globulin (ATG), and total lymphatic irradiation (TLI). The goal of this "immune system reset" is to eradicate the autoreactive lymphocytes responsible for the systemic vasculitis and then re-establish a healthy immune system through the infusion of the autologous HPCs. This pilot study aimed to achieve sustained, treatment-free remission in patients who had failed standard immunosuppressive therapies.
- Other names
- HPC cell-Mounzer Agha-Churg-Strauss syndromeautologous stem cell transplantautologous HPCsHPC cell infusion
Beyond the preview
Go deeper on autologous hematopoietic progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic progenitor cells.